TY  - GEN
AU  - Ennishi,D
AU  - Takeuchi,K
AU  - Yokoyama,M
AU  - Asai,H
AU  - Mishima,Y
AU  - Terui,Y
AU  - Takahashi,S
AU  - Komatsu,H
AU  - Ikeda,K
AU  - Yamaguchi,M
AU  - Suzuki,R
AU  - Tanimoto,M
AU  - Hatake,K
TI  - CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
SN  - 1569-8041
PY  - 2008///1104
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - biosynthesis
KW  - CD5 Antigens
KW  - Cyclophosphamide
KW  - Doxorubicin
KW  - Female
KW  - Humans
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Phenotype
KW  - Prednisone
KW  - Proto-Oncogene Proteins c-bcl-2
KW  - Rituximab
KW  - Vincristine
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1093/annonc/mdn392
ER  -